Skip to content
God Of Sound – Lifestyle
Author:
Kyowa Kirin
New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
June 30, 2026
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
June 29, 2026
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
June 23, 2026
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
June 10, 2026
FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
May 14, 2026
CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program
May 6, 2026